Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1382418 | 0.90 | SMN1; SMN2 (0.49) | ALDH1A1HPGDGAATSHRGFER | |
| SCHEMBL4033037 | 0.90 | SMN1; SMN2 (0.49) | ALDH1A1HPGDGAATSHRGFER | |
| SCHEMBL4035900 | 0.90 | SMN1; SMN2 (0.49) | ALDH1A1HPGDGAATSHRGFER | |
| Hydrochloric Acid SCHEMBL1381183 | 0.89 | SMN1; SMN2 (0.49) | ALDH1A1HPGDGAATSHRGFER | |
| SCHEMBL4035105 | 0.87 | ALDH1A1 (0.48) | ALDH1A1HPGDGAAMAPK1 | |
| SCHEMBL4034695 | 0.86 | GAA (0.51) | ALDH1A1HPGDGAAMAPK1TSHR | |
| SCHEMBL4036675 | 0.86 | ALDH1A1 (0.51) | ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL4365526 | 0.85 | ALDH1A1 (0.49) | ALDH1A1HPGDGAAMAPK1TSHR | |
| SCHEMBL4037427 | 0.85 | TSHR (0.52) | ALDH1A1HPGDGAAMAPK1TSHR | |
| SCHEMBL4035463 | 0.83 | GAA (0.53) | ALDH1A1HPGDGAAMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | claimed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | claimed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | claimed |
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | ALDH1A1 610/4885HPGD 745/4885GAA 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.